An Array Customer is Born as Genaissance Sets To Buy Houston s Lark Technologies for $19M | GenomeWeb

With the joining of Genaissance Pharmaceuticals and Lark Technologies, a new microarray customer may be created.

Genaissance Pharmaceuticals of New Haven, Conn., announced last week that it will acquire Lark Technologies of Houston, in an all-stock transaction worth about $19.9 million.

The deal has been approved by the boards of directors of both publicly traded companies and is expected to close in the first half of 2004, subject to shareholder approval.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.